Pertuzumab adds 16 months survival benefit to trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer
Pertuzumab adds 16 months survival benefit to trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer
New drug anamorelin shows improvement in appetite and body mass in non-small cell lung cancer with cancer anorexia-cachexia
Optimising metastic renal cell carcinoma (mRCC): Treatment lessons from the real world: Introduction
Current treatment options in mRCC
Discussion: Additional treatment options impact first-line treatment of mRCC
The evolving treatment landscape for HER2-positive metastatic breast cancer
Navigating current treatment options for HER2-positive MBC: Patient journey 1
Overview of skin cancer treatments, past, present and future
Advances in CLL: Expert panel Discussion
Emerging treatments in CLL: Expert Discussion
Treatment options in adult chronic idiopathic thrombocytopenic purpura: Introduction
Hot topic: B-cell depletion in adult chronic ITP